Podcast Premier: What You Need to Know About NETSUnderstanding a Neuroendocrine Tumor DiagnosisLearn about the nature of neuroendocrine cells — and what happens when they turn cancerous. In NETRF's premier podcast, we offer an introductory discussion of neuroendocrine tumors by a who's who of NET cancer specialists from leading treatment centers. Physicians discuss the basics of diagnosis, classification, and progression. Particular attention is paid to the frequency of misdiagnosis in this uncommon cancer type. Two patients share their stories of delayed diagnosis and treatment due to the misidentification of symptoms with podcast host Laran Hyder, NETRF Director of Education and Outreach. Listen now and subscribe to get these information-packed episodes on your cell phone or smart speaker today. (MORE)
| |
|
Halfway to Goal!
Thank you to everyone who has participated in our $10 million match campaign. We are pleased to announce we have hit the halfway mark. And it is all because of you! (MORE)
| |
Katherine the Great
Picks a Fight with NETs
"I will never stop fighting," says Katherine Mueller, who has amassed an army of support in her battle to expand our knowledge of NETs. A determined 29-year-old, within months of her NET diagnosis, Mueller along with her family and friends, energized the town of Severna Park, MD, to raise more than $73,000 to fund research for a cancer that had previously been unknown in her close-knit community. See what they did to raise that amount of money for NET research. (MORE)
| |
Rock Star Line Up Planned for NET Patient ConferenceBoston – October 6, 2019We are featuring NET experts from across the nation for our first collaborative patient and caregiver conference with the North American Neuroendocrine Tumor Society (NANETS), the leading professional association for NET doctors. You'll see a wider than ever list of cancer centers represented by physicians of many different disciplines discussing the latest advancements in care. (MORE)
| |
Denver Talks Now Online
Six lectures from the August NET patient and caregiver conference in Denver have been posted to NETRF's YouTube channel. Watch talks on functional v. nonfunctional NETs, surgical treatments, somatostatin analogs, patient/provider communication, and more. (MORE)
| |
Another Chance at HappinessNET Doesn't Stop Missionary Surgeon Two years ago, Steven Arrowsmith, MD saw on an ultrasound screen in Nicaragua that his liver was peppered with lesions and guessed he had two months to live. Since then, he has fallen in love, gotten married, and continues to travel the world to give poor, outcast, injured women another chance at happiness. (MORE)
| |
Talking to Your Doctor Making the Most of a Visit
It can seem like a tall order. Learn all you can about your diagnosis. Find out about every treatment option. And ask an arm's-length list of questions during a 20-minute doctor's visit. Make your next appointment the most productive yet, with a few tried and true techniques for maximizing time in the exam room. (MORE)
| |
Patient, Caregiver, and Provider Input NeededWorldwide NET Survey to Identify Access Issues
The International Neuroendocrine Cancer (INCA) Alliance wants to hear from you. Now through October 31, 2019, this worldwide NET patient advocacy group is conducting a survey to gauge patient access to diagnostic and treatment services. Please take a moment now to offer your insights. (MORE)
| |
Rare Cancer DayTuesday, October 1
It's not easy being a zebra in October when pink ribbons and breast cancer awareness messages are everywhere, even the grocery store. Keep the faith. Know that outreach and advocacy work continues for the lesser-known, less common cancers. Tune in to a free webinar by the National Organization for Rare Disorders (NORD) on October 1, Rare Cancer Day, from 1-2 pm EDT to rally awareness for rare cancers and promote earlier diagnosis. (MORE)
| |
New NANETS Grantee to Explore NET Metastasis Po Hien Ear, PhD, University of Iowa, has been awarded a two-year grant from NANETS, funded by NETRF, to explore laboratory models that support the study of tumor metastasis. The models are also intended to be used to conduct screening of anti-tumor drugs. (MORE)
| |
How Can Scientists Make PRRT More Effective? PRRT works by delivering a radioactive drug (radiotherapeutic agent) to tumor cells where it binds and exposes them to radiation that can kill them. Could weak binding of the drug to the NET cells stand in the way of delivering optimal PRRT treatment? NETRF is funding a pilot study by Kuo-Shyan Lin, PhD, BC Cancer, to try to tighten the binding of PRRT agents to NET cells in order to improve their tumor-killing potential. (MORE)
| |
|
|
|
|
